PROTAC-DB 3.0: an updated database of PROTACs with extended pharmacokinetic parameters
Nucleic Acids Research · 06.01.2025 · 53 (D1) · D1510-D1515
DOI: 10.1093/nar/gkae768 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 03.09.2024. Verfasst von Jingxuan Ge und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058 Zhejiang, China. Hauptthemen laut MEDLINE: Proteolysis, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 143-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Proteolysis-targeting chimera (PROTAC) is an emerging therapeutic technology that leverages the ubiquitin-proteasome system to target protein degradation. Due to its event-driven mechanistic characteristics, PROTAC has the potential to regulate traditionally non-druggable targets. Recently, AI-aided drug design has accelerated the development of PROTAC drugs. However, the rational design of PROTACs remains a considerable challenge. Here, we present an updated online database, PROTAC-DB 3.0. In this third version, we have expanded the database to include 6111 PROTACs (87% increase compared to the 2.0 version). Additionally, the database now contains 569 warheads (small molecules targeting the protein), 2753 linkers, and 107 E3 ligands (small molecules recruiting E3 ligases). The number of target-PROTAC-E3 ternary complex structures has also increased to 959. Recognizing the importance of druggability in PROTAC design, we have incorporated pharmacokinetic data to PROTAC-DB 3.0. To enhance user experience, we have added features for sorting based on molecular similarity and literature publication date. PROTAC-DB 3.0 is accessible at http://cadd.zju.edu.cn/protacdb/.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058 Zhejiang, China.
- CarbonSilicon AI Technology Company, Ltd., Hangzhou 310018Zhejiang, China.
- Polytechnic Institute, Zhejiang University, Hangzhou 310058 Zhejiang, China.
- Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009 Jiangsu, China.
ORCID-Profile: Jingxuan Ge, Gaoqi Weng, Huiyong Sun, Tingjun Hou
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Ge, J., Li, S., Weng, G., Wang, H., Fang, M., Sun, H., Deng, Y., Hsieh, C. Y., Li, D., & Hou, T. (2025). PROTAC-DB 3.0: an updated database of PROTACs with extended pharmacokinetic parameters. Nucleic Acids Research, 53(D1), D1510-D1515. https://doi.org/10.1093/nar/gkae768
Vancouver
Ge J, Li S, Weng G, Wang H, Fang M, Sun H, et al. PROTAC-DB 3.0: an updated database of PROTACs with extended pharmacokinetic parameters. Nucleic Acids Research. 2025;53(D1):D1510-D1515. doi:10.1093/nar/gkae768
BibTeX
@article{Ge2025,
author = {Ge, Jingxuan and Li, Shimeng and Weng, Gaoqi and Wang, Huating and Fang, Meijing and Sun, Huiyong and Deng, Yafeng and Hsieh, Chang-Yu and Li, Dan and Hou, Tingjun},
title = {PROTAC-DB 3.0: an updated database of PROTACs with extended pharmacokinetic parameters},
journal = {Nucleic Acids Research},
year = {2025},
volume = {53},
number = {D1},
pages = {D1510--D1515},
doi = {10.1093/nar/gkae768}
}
EUVIMED